We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.56%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$10.2B
AUM Growth
+$793M
Cap. Flow
+$230M
Cap. Flow %
2.25%
Top 10 Hldgs %
30.33%
Holding
229
New
13
Increased
77
Reduced
41
Closed
15

Top Buys

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.7M
2
TNDM icon
Tandem Diabetes Care
TNDM
+$44M
3
IQV icon
IQVIA
IQV
+$40.5M
4
MGNX icon
MacroGenics
MGNX
+$39.5M
5
SAGE
Sage Therapeutics
SAGE
+$39.1M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$222M
2
MRNA icon
Moderna
MRNA
+$47.8M
3
CI icon
Cigna
CI
+$47.8M
4
BMY icon
Bristol-Myers Squibb
BMY
+$40.5M
5
DVA icon
DaVita
DVA
+$39.6M

Sector Composition

Rank Sector Weight
1 Healthcare 96.41%
2 Industrials 0.94%
3 Technology 0.31%
4 Financials 0.04%
5 Consumer Discretionary 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KOS icon
151
Kosmos Energy
KOS
$1.63B
$1.01M 0.01%
292,000
+97,000
+50% +$301K
RXRX icon
152
Recursion Pharmaceuticals
RXRX
$1.6B
$730K 0.01%
+20,000
New +$592K
RDY icon
153
Dr. Reddy's Laboratories
RDY
$9.83B
$625K 0.01%
42,500
– –
JMIA
154
Jumia Technologies
JMIA
$734M
$546K 0.01%
18,000
– –
FTNT icon
155
Fortinet
FTNT
$111B
$524K 0.01%
11,000
– –
IT icon
156
Gartner
IT
$8.95B
$509K 0.01%
2,100
– –
SPGI icon
157
S&P Global
SPGI
$124B
$493K ﹤0.01%
1,200
– –
DPZ icon
158
Domino's
DPZ
$10.7B
$466K ﹤0.01%
1,000
– –
MCK icon
159
McKesson
MCK
$96.5B
$465K ﹤0.01%
2,430
– –
MCO icon
160
Moody's
MCO
$82.5B
$453K ﹤0.01%
1,250
– –
INTU icon
161
Intuit
INTU
$77B
$441K ﹤0.01%
900
– –
TW icon
162
Tradeweb Markets
TW
$21.3B
$440K ﹤0.01%
5,200
– –
MSCI icon
163
MSCI
MSCI
$40.2B
$435K ﹤0.01%
816
– –
AXP icon
164
American Express
AXP
$233B
$430K ﹤0.01%
2,600
– –
EL icon
165
Estee Lauder
EL
$28.9B
$429K ﹤0.01%
1,348
– –
POOL icon
166
Pool Corp
POOL
$6.68B
$413K ﹤0.01%
900
– –
LYV icon
167
Live Nation Entertainment
LYV
$41B
$412K ﹤0.01%
4,700
– –
TRU icon
168
TransUnion
TRU
$14.2B
$406K ﹤0.01%
3,696
– –
SWKS icon
169
Skyworks Solutions
SWKS
$9.1B
$403K ﹤0.01%
2,100
– –
A icon
170
Agilent Technologies
A
$39.5B
$399K ﹤0.01%
2,700
– –
OPT
171
DELISTED
Opthea Limited American Depositary Shares
OPT
$397K ﹤0.01%
50,000
– –
TRMB icon
172
Trimble
TRMB
$11.7B
$393K ﹤0.01%
4,800
– –
VRSN icon
173
VeriSign
VRSN
$23.8B
$387K ﹤0.01%
1,700
– –
MTCH icon
174
Match Group
MTCH
$8.72B
$383K ﹤0.01%
2,378
– –
ULTA icon
175
Ulta Beauty
ULTA
$20.5B
$380K ﹤0.01%
1,100
– –
5 6
7
8 9

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2021 Portfolio in Review

As of Q2 2021, Bellevue Group held 229 positions worth $10.2B, up 8.4% from $9.45B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Bellevue Group's Q2 2021 filing shows 13 new, 77 increased, 41 reduced and 15 closed positions. Its largest new stake was Adaptive Biotechnologies: 962,352 shares worth $39.3M. The largest sale was Alexion Pharmaceuticals, an estimated $222M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q2 2021 buy was Adaptive Biotechnologies: 962,352 shares worth $39.3M.
  • Bellevue Group added most to Vertex Pharmaceuticals in Q2 2021, an estimated $74.7M increase.
  • Bellevue Group's biggest Q2 2021 reduction was Alexion Pharmaceuticals, cutting an estimated $222M.
  • Bellevue Group fully exited DaVita in Q2 2021, selling an estimated $39.6M.
  • Bellevue Group's ten largest holdings make up 30% of its $10.2B portfolio in Q2 2021.
  • Bellevue Group opened 13 new positions and closed 15 in Q2 2021.
  • Bellevue Group's portfolio value rose 8.4% quarter-over-quarter to $10.2B.

Based on Bellevue Group's 13F filing for Q2 2021, filed 12 Aug 2021.